NL-OMON40889已完成不适用
Single center, open-label, non-randomized, non-placebo-controlled study to investigate the pharmacokinetics, metabolic disposition and mass balance after single administration of 5 mg [14C]BAY 1021189 (oral solution) in healthy male subjects - BAY 1021189 Mass Balance Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male subjects
- •45-65 yrs, inclusive
- •BMI: 18.0-30.0 kg/m2, inclusive
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
Single center, open-label, non-randomized, non-placebo-controlled study to investigate the metabolism, excretion pattern, mass balance, safety, tolerability and pharmacokinetics after single administration of 200 mg [14C]rogaratinib (oral solution) in healthy male subjectsNL-OMON46572Bayer AG6
已完成
不适用
Single center, open-label, non-randomized, non-placebo-controlled study to investigate the pharmacokinetics, metabolic disposition and mass balance after single administration of 25 mg [14C]BAY 2433334 (oral solution) in healthy male participants.strokeNL-OMON50127Bayer AG6
已完成
不适用
Single center, open label, non-randomized, non-placebo controlled study to investigate the pharmacokinetics, metabolic disposition, and mass balance after single administration of 20 mg [14C]neladenoson bialanate (oral solution) in healthy male subjects.10019280heart failureNL-OMON44620Bayer AG6
尚未招募
Unknown
Exploring Safety and Effectiveness of HI-GRIP VC Bandage for Chronic Leg UlcersCTRI/2024/07/070977Outcare Medical Device Pvt Ltd
进行中（未招募）
1 期
A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of MLD patients with high residual level of voluntary functioEUCTR2007-007165-20-DKShire Pharmaceuticals Ireland Limited6